Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261046 | 0.89 | AVPR1B (0.58) | AVPR1BCYP3A4 | |
| SCHEMBL1875220 | 0.89 | AVPR1B (0.58) | AVPR1BCYP3A4 | |
| SCHEMBL16837244 | 0.89 | AVPR1B (0.58) | AVPR1BCYP3A4 | |
| SCHEMBL1590457 | 0.88 | AVPR1B (0.61) | AVPR1B | |
| SCHEMBL1589499 | 0.87 | AVPR1B (0.57) | AVPR1B | |
| SCHEMBL3841463 | 0.85 | AVPR1B (0.66) | AVPR1B | |
| SCHEMBL2892463 | 0.84 | AVPR1B (1.00) | AVPR1BCYP3A4 | |
| SCHEMBL1588304 | 0.83 | AVPR1B (0.52) | AVPR1B | |
| SCHEMBL16178114 | 0.83 | AVPR1B (0.63) | AVPR1B | |
| SCHEMBL1786304 | 0.83 | AVPR1B (0.63) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3143023-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9527856-B2 | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| EP-2227463-B1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBVIE DEUTSCHLAND (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-9238642-B2 | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-03 | — | — | US | disclosed |
| WO-2015173392-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2227463-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | Abbott GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | disclosed |
| EP-2114921-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114922-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009083559-A1 | SUBSTITUTED OXINDOLE-DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008080971-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080970-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080972-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885 |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.